Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Mutations in the superoxide dismutase 1 (SOD1) gene are a rare cause of ALS.
• Current ALS treatments are limited, highlighting the need for disease-modifying therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of tofersen in patients with SOD1-mutated ALS.
• To assess tofersen's impact on biomarkers of neuroaxonal injury and SOD1 protein levels.
• To investigate the long-term effects of tofersen on functional outcomes in ALS.

Main Methods:

• Phase III, multinational, randomized, placebo-controlled VALOR trial.
• Intrathecal administration of tofersen.
• Measurement of plasma neurofilament light chain and cerebrospinal fluid SOD1 protein levels.
• Assessment of functional outcomes using ALS rating scales.

Main Results:

• Tofersen significantly reduced plasma neurofilament and CSF SOD1 protein levels.
• Reductions in biomarkers were sustained during the open-label extension.
• No significant difference in functional decline between tofersen and placebo in the initial 28-week trial.
• Early tofersen initiation in the extension study was associated with slowed functional decline.

Conclusions:

• Tofersen is the first approved disease-modifying therapy for SOD1-ALS.
• It demonstrates a favorable benefit-to-risk profile.
• Tofersen reduces key biomarkers of neurodegeneration in ALS patients with SOD1 mutations.